Neuro-Nutrition in Migraine Infographic 

Neuro-Nutrition and the Mitochondria–Migraine Connection: Migraine as a Disorder of Brain Energy Homeostasis. From a purely vascular model to a neurovascular and metabolic model, with targeted nutritional adjuncts.

Migraine effects roughly one in seven people worldwide and ranks second among all causes of years lived with disability, first among young women [1]. The diagnosis remains clinical and relies on ICHD-3, which requires, for migraine without aura, at least five attacks lasting 4–72 hours with at least two of four pain features and either nausea/vomiting or both photophobia and phonophobia, and no better explanation [2]. For decades the dominant explanation was vascular: intracranial vasoconstriction produced aura and rebound vasodilation produced pain. That model failed on several fronts: aura propagates across cortex independently of vascular territories, vasodilators do not reliably trigger attacks in all patients, and the model says nothing about why the brain of a person with migraine is abnormal between attacks. The modern view treats migraine as a neurovascular disorder in which the vascular changes are downstream [5]. A parallel body of work, summarised by Gross and colleagues, proposes that a mismatch between brain energy supply and demand is a fundamental vulnerability that makes the migraine brain easily overwhelmed by ordinary stressors [3]. This essay reviews that hypothesis, the nutritional interventions derived from it and how a clinician should use them.

Why an energy hypothesis?

Several independent lines of evidence converge.

Clinical and genetic observations. Migraine-like headache is a common feature of primary mitochondrial diseases such as MELAS. Familial hemiplegic migraine, the best-characterised monogenic form, results from mutations in CACNA1A, ATP1A2 and SCN1A, genes that regulate ion fluxes whose restoration consumes a large share of neuronal ATP. Typical triggers, including fasting, missed meals, sleep deprivation, strenuous exercise, alcohol, and hormonal fluctuation, are all states that either reduce substrate supply or increase energy demand [3].

Biochemical and imaging evidence. Phosphorus magnetic resonance spectroscopy (31P-MRS) studies from the 1990s reported reduced phosphorylation potential and impaired oxidative metabolism in the brain and skeletal muscle of patients with migraine between attacks [6,7]. Interictal FDG-PET studies have shown regional hypometabolism in several cortical and subcortical areas [8]. The studies are heterogeneous, mostly small and not uniformly replicated, but the direction of findings is consistent.

Neurophysiology. The migraine cortex shows deficient habituation to repeated sensory stimuli (visual and somatosensory evoked potentials) between attacks. Habituation is partly an energy-dependent process, and the deficit is correlated with reduced mitochondrial energy reserve; it normalises during an attack and, in some studies, after riboflavin or beta-blocker prophylaxis [9]. The picture is better described as a hyperresponsive, energy-limited cortex than a simply hyperexcitable one.

Oxidative stress and cortical spreading depolarization (CSD). CSD, a slowly propagating wave of neuronal and glial depolarization, is the physiological correlate of aura and can activate trigeminal afferents [4]. Recovery from CSD demands a large burst of ATP-dependent Na+/K+ pumping. Mitochondrial dysfunction and reactive oxygen species may lower the threshold for CSD and sensitise trigeminal nociceptors; many classic migraine triggers can be linked to oxidative stress [10]. This is biologically plausible, but most of the causal evidence comes from animal models.

Systemic metabolic links. Obesity is a risk factor for migraine chronification [21]; adipose tissue releases leptin and pro-inflammatory adipokines, and adipokine levels shift with migraine status. The gut–brain axis (short-chain fatty acids, serotonin, and CGRP signalling along enteric–trigeminal pathways) offers another plausible metabolic link, although human data remain preliminary.

Where the hypothesis stands in relation to current therapy

It is important to be candid about the hierarchy of evidence. CGRP-targeted therapies (gepants and monoclonal antibodies against CGRP or its receptor) and established preventives (topiramate, propranolol, amitriptyline, onabotulinumtoxinA for chronic migraine) have the strongest evidence and define modern preventive care [25,26]. The bioenergetic hypothesis does not compete with this pathway; mitochondrial dysfunction and CGRP signalling probably interact, since oxidative stress and CSD both activate the trigeminovascular system. Nutritional strategies should therefore be framed as low-risk adjuncts or alternatives for selected patients: those who prefer non-drug options, who cannot tolerate or have contraindications to conventional preventives, who are pregnant or planning pregnancy (with appropriate caution), or who want to add something to partial responders.

The substrate interventions

Riboflavin (vitamin B2). Riboflavin is the precursor of FMN and FAD, prosthetic groups of complex I and complex II of the respiratory chain. In the pivotal placebo-controlled trial, 400 mg daily for three months produced a 50% responder rate of 59% versus 15% with placebo [11]. It is classified as Level B (probably effective) in the 2012 AAN/AHS guideline [14] and carries a strong, low-quality recommendation from the Canadian Headache Society [27]. Practical points: benefit is typically seen after 2–3 months; it is safe and inexpensive; urine turns bright yellow, and mild gastrointestinal upset or polyuria can occur. Later trials, particularly in children and in some adult cohorts, have been inconsistent, so patient expectations should be realistic.

Coenzyme Q10. CoQ10 shuttles electrons from complexes I and II to complex III and acts as a lipid-soluble antioxidant. In a randomised trial, 300 mg/day (100 mg three times daily) gave a 50% responder rate of 47.6% versus 14.4% with placebo after three months [12]; meta-analyses suggest reductions in attack frequency and duration with doses of 100–400 mg/day, with some lower-dose evidence at 150 mg [15]. The guideline grade is Level C. Practical points: take with fat-containing food for absorption; generally well tolerated; it may reduce the anticoagulant effect of warfarin [29], so INR should be monitored.

Magnesium. Magnesium is the voltage-dependent blocker of the NMDA receptor channel, is required for all ATP-dependent reactions, and low ionised magnesium has been reported in some patients with migraine. Oral trimagnesium dicitrate, 600 mg (24 mmol) daily, reduced attack frequency in a placebo-controlled trial [13], and the 2012 guideline assigns Level B [14]. Meta-analyses of intravenous magnesium for acute attacks are mixed, and it is not a first-line acute option [28]. Practical points: diarrhea is the most common adverse effect (citrate, glycinate or slow-release forms are better tolerated than oxide, which is poorly absorbed); avoid or reduce in significant renal impairment; separate from interacting drugs (e.g., some antibiotics, bisphosphonates).

Fixed-dose combination. A randomised trial of a combination of riboflavin 400 mg, magnesium 600 mg and CoQ10 150 mg reported fewer migraine days than placebo over three months, although the effect size was modest [15].

Alpha-lipoic acid (ALA). ALA is a mitochondrial cofactor (pyruvate and alpha-ketoglutarate dehydrogenase) and a potent antioxidant. The only randomised trial of 600 mg/day missed its primary endpoint, with a non-significant trend in responder rate [16]. Smaller open-label studies are positive. ALA therefore has no guideline grade and should be seen as experimental. Practical points: it can lower blood glucose, with rare cases of insulin autoimmune syndrome reported in susceptible genotypes; it should be used cautiously in patients on insulin or sulfonylureas.

Probiotics. A randomised trial of a multispecies probiotic reported reductions in migraine frequency and severity [17], but data are limited and strain-specific. They are low-risk but not evidence-based as a standard recommendation.

Diet and lifestyle

The best-supported dietary advice is consistency: regular meals, avoidance of prolonged fasting, adequate hydration, stable caffeine intake, regular sleep and moderate aerobic exercise. A headache diary is more informative than any elimination protocol. IgG-guided elimination diets are not recommended: allergy societies advise against IgG testing as a diagnostic tool, as IgG reflects exposure rather than sensitivity [24], and the single double-blind trial of an IgG-based diet gave a modest reduction in migraine days that did not meet its primary endpoint [23]. Weight reduction in patients with obesity is reasonable given the link with chronification [21]. Short-term ketogenic diets, which supply ketone bodies as an alternative mitochondrial fuel, have shown promising results in small studies, and are a coherent test of the bioenergetic hypothesis, but remain investigational and difficult to sustain [22].

Precision nutrition: MTHFR and homocysteine

The C677T variant of MTHFR reduces enzyme activity and raises homocysteine, and the TT genotype is associated with migraine with aura in meta-analysis [18]. In one supplementation study, folic acid 2 mg, vitamin B6 25 mg and vitamin B12 400 µg lowered homocysteine and migraine disability in patients with aura, with genotype influencing the homocysteine response [19]. However, the clinical benefit was not clearly genotype-dependent, the trials are small, and ACMG explicitly advises against routine MTHFR genotyping in clinical practice because results rarely change management [20]. A pragmatic approach is to consider measuring homocysteine and B12/folate status in migraine with aura, and to treat deficiency, rather than genotyping. Safety points: chronic B6 doses above about 100 mg/day risk sensory neuropathy; folic acid can mask B12 deficiency; check B12 before long-term folate.

A practical clinical approach

1. Confirm the diagnosis (ICHD-3), exclude secondary causes and red flags, and record a baseline of monthly migraine days and acute medication days.
2. Treat modifiable factors: sleep, regular meals, hydration, obesity, medication overuse, depression and anxiety.
3. Offer evidence-graded preventives first when frequency or disability warrants (conventional or CGRP-targeted), and discuss supplements as add-ons or alternatives.
4. Choose supplements by evidence and safety: riboflavin 400 mg daily and magnesium 400–600 mg elemental daily (Level B); CoQ10 150–300 mg daily (Level C). Start one agent at a time or use a combination product, and document it.
5. Allow three months before judging response; stop if less than about a 25–30% reduction in monthly migraine days.
6. Check interactions and comorbidities: warfarin (CoQ10), renal function (magnesium), diabetes medications (ALA), vitamin B6 dose.
7. Be honest with patients: these agents are preventive, not acute treatments, and effect sizes are modest and variable.

Limitations and research directions

The bioenergetic hypothesis has important limitations. Many imaging and biochemical studies are small and cross-sectional; it remains uncertain whether energy changes are a cause, a consequence or an epiphenomenon. Supplement trials vary in dose, population and endpoint, have frequent placebo responses (which are high in migraine), and were often funded by supplement manufacturers. Direct measurement of mitochondrial function in vivo is difficult. Future work should include biomarker-stratified trials (for example, patients with documented energy deficit on 31P-MRS or with specific mtDNA haplogroups), standardised dosing, and head-to-head comparison with, or add-on testing alongside, CGRP-pathway drugs.

Conclusion

Migraine is best understood as a neurovascular disorder in which a brain with limited energy reserve is repeatedly overwhelmed by ordinary metabolic and sensory challenges. This view explains triggers, interictal abnormalities and the rationale for riboflavin, CoQ10 and magnesium, which have modest but real evidence and an excellent safety profile. For the practising clinician, the key messages are: use correct diagnostic criteria; place nutritional strategies within, not above, evidence-based preventive care; give them a full three-month trial with a diary; screen for interactions; and avoid unsupported tests and restrictive diets. The infographic is a useful teaching tool once its numerical errors and its overstated ‘paradigm shift’ framing are corrected.

---

References

1. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137.
2. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia. 2018;38(1):1–211.
3. Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J. The metabolic face of migraine: from pathophysiology to treatment. Nat Rev Neurol. 2019;15:627–643.
4. Charles AC, Baca SM. Cortical spreading depression and migraine. Nat Rev Neurol. 2013;9:637–644.
5. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553–622.
6. Montagna P, Cortelli P, Monari L, et al. 31P-magnetic resonance spectroscopy in migraine without aura. Neurology. 1994;44:666–669.
7. Lodi R, Kemp GJ, Montagna P, et al. Quantitative analysis of skeletal muscle bioenergetics and proton efflux in migraine and cluster headache. J Neurol Sci. 1997;146:73–80.
8. Kim JH, Kim S, Suh SI, Koh SB, Park KW, Oh K. Interictal metabolic changes in episodic migraine: a voxel-based FDG-PET study. Cephalalgia. 2010;30:53–61.
9. Coppola G, Pierelli F, Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? Cephalalgia. 2007;27:1427–1439.
10. Borkum JM. Migraine triggers and oxidative stress: a narrative review and synthesis. Headache. 2016;56:12–35.
11. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology. 1998;50:466–470.
12. Sándor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64:713–715.
13. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16:257–263.
14. Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology. 2012;78:1346–1353.
15. Gaul C, Diener HC, Danesch U; Migravent Study Group. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain. 2015;16:32.
16. Magis D, Ambrosini A, Sándor P, Jacquy J, Laloux P, Schoenen J. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache. 2007;47:52–57.
17. Martami F, Togha M, Seifishahpar M, et al. The effects of a multispecies probiotic supplement on inflammatory markers and episodic and chronic migraine characteristics: a randomized double-blind controlled trial. Cephalalgia. 2019;39:841–853.
18. Rubino E, Ferrero M, Rainero I, et al. Association of the C677T polymorphism in the methylenetetrahydrofolate reductase gene with migraine: a meta-analysis. Cephalalgia. 2009;29:818–825.
19. Lea R, Colson N, Quinlan S, Macmillan J, Griffiths L. The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet Genomics. 2009;19:422–428.
20. Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013;15:153–156.
21. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology. 2006;67:252–257.
22. Di Lorenzo C, Coppola G, Sirianni G, et al. Migraine improvement during short lasting ketogenesis: a proof-of-concept study. Eur J Neurol. 2015;22:170–177.
23. Alpay K, Ertas M, Orhan EK, Ustay DK, Lima C, Baykan B. Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. Cephalalgia. 2010;30:829–837.
24. Stapel SO, Asero R, Ballmer-Weber BK, et al. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy. 2008;63:793–796.
25. Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021–1039.
26. Diener HC, Charles A, Goadsby PJ, Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015;14:1010–1022.
27. Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2):S1–S59.
28. Chiu HY, Yeh TH, Huang YC, Chen PY. Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Pain Physician. 2016;19:E97–E112.
29. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet. 1994;344:1372–1373.